Limbic
Category: AI in Healthcare
Clinical AI platform for mental healthcare that provides AI-powered patient intake, triage, and therapy support, proven to outperform human clinicians in delivering CBT. Limbic was founded in 2017. The company is led by Dr. Ross Harper. Based in London, United Kingdom (also New York, NY). Team size: 11-50. Total funding raised: $14.7M. Latest round: Series A. Key investors include Khosla Ventures, 7percent Ventures, Gaingels, Illusian (Ilkka Paananen family office), AI Seed, Entrepreneur First, Joyance Partners, Social Starts, Charlie Songhurst.
- Founded
- 2017
- Headquarters
- London, United Kingdom (also New York, NY)
- Team size
- 11-50
- Total funding
- $14.7M
Value proposition
Clinically validated AI that expands mental healthcare capacity by automating intake, triage, and therapy support — proven to reduce wait times, increase access for underserved populations, and improve recovery rates while being the only Class IIa medical device certified AI chatbot for mental health.
Products and solutions
Limbic Access (AI-powered patient intake and clinical assessment chatbot for self-referral and triage), Limbic Care (AI therapy companion with ambient scribe, CBT support between sessions, and clinical decision support), Limbic Layer (proprietary clinical reasoning system that sits between LLMs and patients to ensure safe, validated clinical decisions)
Unique value
Only AI mental health chatbot with UKCA Class IIa medical device certification; proven in a Nature Medicine randomized double-blind trial to outperform licensed human therapists in delivering CBT; deployed across 33% of NHS Talking Therapies services; proprietary Limbic Layer clinical reasoning system ensures safety and compliance.
Target customer
Health plans, behavioral health providers, health systems, and NHS Talking Therapies services
Industries served
Mental healthcare, Behavioral health, NHS Talking Therapies, Health plans, Health systems
Technology advantage
Proprietary "Limbic Layer" clinical reasoning system that wraps around LLMs (OpenAI, Anthropic, Google, Meta) to ensure all clinical decisions are based on validated guidance. Class IIa medical device regulatory status. HIPAA, GDPR, and ISO 27001 compliant. Interoperable with EHR systems. 10 PhDs across neuroscience, psychiatry, ML, and medicine on the team.
How they differentiate
Limbic is the only AI mental health platform with Class IIa medical device certification (UKCA), meaning it must conform to rigorous clinical risk management, safety, and efficacy standards. Its Nature Medicine study (March 2026) showed AI therapy agents using the Limbic Layer outperformed both human clinicians and leading LLMs in CBT delivery. The company has deep NHS integration (33% of UK Talking Therapies services) and a strong evidence base with 8,500+ academic citations.
Main competitors
Woebot Health, Wysa, Slingshot AI
Key partnerships
NHS Confederation (partnership to explore AI adoption in mental health services, announced Dec 2025), NHS Talking Therapies (deployed across 33% of UK services), Rogers Behavioral Health (US deployment of Limbic Access), Everyturn Mental Health, Essex Partnership University Trust
Notable customers
NHS Talking Therapies (33% of UK services), Rogers Behavioral Health, Everyturn Mental Health, Essex Partnership University Trust, NHS Bradford and Craven District Talking Therapies, Living Well Consortium
Major milestones
2020: Launched Limbic AI platform, 2021: First AI mental health chatbot to achieve UKCA Class IIa medical device status, 2024: Raised $14M Series A led by Khosla Ventures, 2024: Expanded to US market with Rogers Behavioral Health deployment, 2025: Partnership with NHS Confederation, 2026: Nature Medicine study shows AI outperforms human therapists in CBT delivery, 2026: Limbic Care upgraded with regulated AI scribe technology for NHS
Growth metrics
Helped 650,000+ patients access mental healthcare; deployed across 33% of NHS Talking Therapies services; clinicians reclaimed 50,000+ hours of assessment work; 179% increase in nonbinary individuals seeking care; 29% increase in minority referrals; 2x recovery rates; 23% lower dropout rates
Market positioning
Limbic is the most clinically validated and regulated AI mental health platform, positioned as the enterprise-grade solution for health systems and providers. It differentiates from consumer-focused apps (Woebot, Wysa) through its medical device certification, deep NHS integration, and proven ability to integrate into clinical workflows as a B2B SaaS platform rather than a direct-to-consumer app.
Geographic focus
UK (dominant in NHS) and US (expanding with Series A funding)
Patents and IP
Proprietary "Limbic Layer" clinical reasoning system; UKCA Class IIa medical device certification for AI diagnostic support
About Dr. Ross Harper
PhD in Computational Neuroscience, UCL; MRes in Mathematical Modelling in Biology, UCL; MA in Natural Sciences, University of Cambridge. Lloyd's Bank New Entrepreneur of the Year. Project Lead for Horizon 2020 and Innovate UK grants.
Latest news about Limbic
More AI in Healthcare companies
Official website: https://limbic.ai